Linked Life Data

20958322

Source:http://linkedlifedata.com/resource/pubmed/id/20958322

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:dateCreated
2010-10-20
pubmed:abstractText
The concept of immunogenic chemotherapy that has recently emerged relies upon the capacity of a cytotoxic compound to trigger a cell-death modality. This modality elicits cross-priming by dendritic cells of tumor antigen-specific T cells that will contribute to the tumoricidal activity of the compound and protect the host against relapse. In contrast, most anticancer drugs elicit nonimmunogenic apoptosis that is not accompanied with an immunizing property. This review will discuss some molecular and metabolic changes required at the level of the tumor that must engage key pathways at the level of the host for the induction of Tc1 polarized-protective T cell responses during chemotherapy. We will summarize the immune adjuvants that can boost the immunogenicity of cell death to augment the efficacy of chemotherapy.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Oct
pubmed:issn
1749-6632
pubmed:author
pubmed:copyrightInfo
© 2010 New York Academy of Sciences.
pubmed:issnType
Electronic
pubmed:volume
1209
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
99-108
pubmed:meshHeading
pubmed:year
2010
pubmed:articleTitle
Desirable cell death during anticancer chemotherapy.
pubmed:affiliation
Institut National de la Santé et de la Recherche Médicale, U1015, Villejuif, France.
pubmed:publicationType
Journal Article, Review